{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:31:46Z","timestamp":1761895906826,"version":"build-2065373602"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.clml.2014.04.008","type":"journal-article","created":{"date-parts":[[2014,6,12]],"date-time":"2014-06-12T12:46:54Z","timestamp":1402577214000},"page":"431-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Follicular Lymphoma Grade 3: Review and\u00a0Updates"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5458-8423","authenticated-orcid":false,"given":"Gayatri","family":"Vaidyanathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.04.008_bib1","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","article-title":"A\u00a0Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma","volume":"89","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.critrevonc.2008.01.014","article-title":"Follicular lymphomas","volume":"66","author":"Vitolo","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clml.2014.04.008_bib3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/00000478-199208000-00011","article-title":"Incorporation of immunostaining data in anatomic pathology reports","volume":"16","author":"Banks","year":"1992","journal-title":"Am J Surg Pathol"},{"year":"1978","series-title":"Malignant Lymphomas Other than Hodgkin's Disease: Histology, Cytology, Ultrastructure, Immunology","author":"Lennert","key":"10.1016\/j.clml.2014.04.008_bib4"},{"key":"10.1016\/j.clml.2014.04.008_bib5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib6","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November 1997","volume":"17","author":"Harris","year":"1999","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/CCO.0b013e3282c9ad78","article-title":"Natural history of follicular grade 3 non-Hodgkin's lymphoma","volume":"19","author":"Bierman","year":"2007","journal-title":"Curr Opin Oncol"},{"year":"2008","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdllow","key":"10.1016\/j.clml.2014.04.008_bib8"},{"key":"10.1016\/j.clml.2014.04.008_bib9","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1182\/blood.V91.11.4292","article-title":"Analysis of VH genes in follicular and diffuse lymphoma shows ongoing somatic mutation and multiple isotype transcripts in early disease with changes during disease progression","volume":"91","author":"Ottensmeier","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1309\/2GFKU23XA1DH38L7","article-title":"Abnormal patterns of antigenic expression in follicular lymphoma a flow cytometric study","volume":"124","author":"Ray","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2014.04.008_bib11","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/sj.leu.2403738","article-title":"Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances","volume":"19","author":"Guo","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.04.008_bib12","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1309\/B6MK-J7NF-A6JP-X56K","article-title":"Decreased CD10 expression in grade III and in interfollicular infiltrates of follicular lymphomas","volume":"115","author":"Eshoa","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2014.04.008_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1309\/TNKL7GDC66R9WPV5","article-title":"Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma","volume":"121","author":"Bilalovic","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.clml.2014.04.008_bib14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3324\/haematol.10682","article-title":"MUM1 expression dichotomizes follicular lymphoma into predominantly, MUM1-negative low-grade and MUM1-positive high-grade subtypes","volume":"92","author":"Naresh","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.04.008_bib15","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2006-09-045989","article-title":"CD10\u2212 MUM1+ follicular lymphoma lacks BCL2 gene translocation and shows characteristic biologic and clinical features","volume":"109","author":"Karube","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJM198701083160204","article-title":"Multiple recurrent genomic defects in follicular lymphoma","volume":"316","author":"Yunis","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.008_bib17","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0092-8674(85)80070-2","article-title":"Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18","volume":"41","author":"Bakhshi","year":"1985","journal-title":"Cell"},{"key":"10.1016\/j.clml.2014.04.008_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0092-8674(86)90362-4","article-title":"Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2\/immunoglobulin transcript resulting from the t(14;18) translocation","volume":"47","author":"Cleary","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.clml.2014.04.008_bib19","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1056\/NEJM198806233182502","article-title":"Expression in non-Hodgkin lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation","volume":"318","author":"Ngan","year":"1988","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.04.008_bib20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0002-9440(10)63313-5","article-title":"Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component","volume":"165","author":"Katzenberger","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1016\/j.clml.2014.04.008_bib21","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.pas.0000172191.87176.3b","article-title":"Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features","volume":"29","author":"Wang","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2014.04.008_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ijc.20354","article-title":"Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation or cyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index","volume":"112","author":"Pruneri","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2014.04.008_bib23","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma","volume":"85","author":"Martin","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib24","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib25","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3324\/haematol.2011.042531","article-title":"Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles","volume":"96","author":"Horn","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.04.008_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/10428190310001593120","article-title":"The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases","volume":"45","author":"Au","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.04.008_bib27","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10428190701836845","article-title":"C-MYC translocation in t(14;18) positive follicular lymphoma at presentation: an adverse prognostic indicator?","volume":"49","author":"Christie","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2014.04.008_bib28","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0165-4608(00)00383-6","article-title":"Chromosomal analyses of 52\u00a0cases of follicular lymphoma with t(14;18), including blastic\/blastoid variant","volume":"126","author":"Mohamed","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.clml.2014.04.008_bib29","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1182\/blood.V77.7.1508.1508","article-title":"Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin lymphoma: clinical correlations","volume":"77","author":"Offit","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib30","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood.V80.3.758.758","article-title":"MYC rearrangements in histologically progressed follicular lymphomas","volume":"80","author":"Yano","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib31","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V101.3.1149","article-title":"Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive","volume":"101","author":"Bosga-Bouwer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.beha.2011.02.002","article-title":"Follicular lymphoma grade 3B","volume":"24","author":"Salaverria","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2014.04.008_bib33","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.1986.4.10.1470","article-title":"Follicular lymphoma: prognostic factors for response and survival","volume":"4","author":"Gallagher","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib34","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.1998.16.8.2780","article-title":"New approach to classifying non-Hodgkin lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project","volume":"16","author":"Armitage","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib35","doi-asserted-by":"crossref","first-page":"863","DOI":"10.5858\/2004-128-863-ACEOFL","article-title":"A\u00a0clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences","volume":"128","author":"Hsi","year":"2004","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.clml.2014.04.008_bib36","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib37","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1200\/JCO.2008.18.1495","article-title":"Follicular lymphoma in the United States: first report of the national LymphoCare study","volume":"27","author":"Friedberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib38","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib39","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1365-2141.2011.08942.x","article-title":"Clinical significance of the WHO grades of\u00a0follicular lymphoma in a population-based cohort of 505 patients with long follow-up times","volume":"156","author":"Wahlin","year":"2012","journal-title":"Br J Hematol"},{"key":"10.1016\/j.clml.2014.04.008_bib40","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1200\/JCO.1993.11.2.218","article-title":"Clinical features and prognosis of follicular large-cell lymphoma: a report from the Nebraska Lymphoma Study Group","volume":"11","author":"Anderson","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib41","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A\u00a0significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib42","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/blood.V93.7.2202","article-title":"Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features","volume":"93","author":"Rodriguez","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/sj.bjc.6601006","article-title":"Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?","volume":"89","author":"Chau","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clml.2014.04.008_bib44","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib45","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients","volume":"24","author":"\u00c1lvaro","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib46","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial","volume":"26","author":"Canioni","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib47","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL)","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib48","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"Hiddemann","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.beha.2011.02.006","article-title":"Transformation of follicular lymphoma","volume":"24","author":"Lossos","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2014.04.008_bib50","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/1097-0142(19840301)53:5<1109::AID-CNCR2820530516>3.0.CO;2-O","article-title":"Malignant lymphomas of follicular center cell origin in humans. V. Incidence, clinical features, and prognostic implications of transformation of small cleaved cell nodular lymphoma","volume":"53","author":"Oviatt","year":"1984","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2014.04.008_bib51","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1200\/JCO.1997.15.4.1587","article-title":"Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients","volume":"15","author":"Bastion","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib52","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1200\/JCO.2006.09.3260","article-title":"Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma","volume":"25","author":"Montoto","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib53","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2559.2001.01120.x","article-title":"Pathology of lymphoma progression","volume":"38","author":"M\u00fcller-Hermelink","year":"2001","journal-title":"Histopathology"},{"key":"10.1016\/j.clml.2014.04.008_bib54","doi-asserted-by":"crossref","first-page":"626035","DOI":"10.1155\/2012\/626035","article-title":"Exploring risk factors for follicular lymphoma","volume":"2012","author":"Ambinder","year":"2012","journal-title":"Adv Hematol"},{"key":"10.1016\/j.clml.2014.04.008_bib55","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/01.cej.0000220629.00729.65","article-title":"Case-control study of lymphoid neoplasm in three French areas: description, alcohol and tobacco consumption","volume":"16","author":"Casey","year":"2007","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.clml.2014.04.008_bib56","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1055-9965.EPI-04-0693","article-title":"Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph)","volume":"14","author":"Morton","year":"2005","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clml.2014.04.008_bib57","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1002\/ijc.22762","article-title":"Obesity and risk of non-Hodgkin lymphoma: a meta-analysis","volume":"121","author":"Larsson","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.clml.2014.04.008_bib58","first-page":"224","article-title":"The incidence of non-Hodgkin lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants","volume":"7","author":"Herrinton","year":"1996","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clml.2014.04.008_bib59","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdl039","article-title":"Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience","volume":"17","author":"Ganti","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib60","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/asheducation-2006.1.303","article-title":"Controversies in follicular lymphoma: \u201cwho, what, when, where, and why?\u201d (not necessarily in that order!)","author":"Czuczman","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2014.04.008_bib61","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/annonc\/mdm511","article-title":"The addition of rituximab to CHOP chemotherapy improves overall and failure-free survival for follicular grade 3 lymphoma","volume":"19","author":"Overman","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.04.008_bib62","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1182\/blood-2008-04-153189","article-title":"Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study","volume":"112","author":"Salles","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib63","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1182\/blood-2006-03-013193","volume":"108","author":"Sebban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib64","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2008-05-160200","article-title":"High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years","volume":"113","author":"Gyan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.04.008_bib65","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1182\/blood-2007-10-116749","volume":"111","author":"Ladetto","year":"2008","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265014001505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:17Z","timestamp":1761870377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265014001505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S2152265014001505"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.04.008","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Follicular Lymphoma Grade 3: Review and\u00a0Updates","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}